Santen Pharmaceutical Co. Ltd., of Osaka, Japan, agreed to acquire shares representing 50.55 percent of the share capital of ophthalmology firm Novagali Pharma SA, of Paris, for a cash consideration of €6.15 (US$8.35), or about $136 million, marking a premium of 71.3 percent over the Sept. 27 trading price, which could be increased to €6.25.